Laboratoire PRISM Inserm U1192 |

The PRISM laboratory (Proteomics, Inflammatory Response, Mass Spectrometry), U1192 Inserm, is dedicated to technological and therapeutic innovations for precision medicine. PRISM Inserm U1192 creates and develops new technologies, new biological concepts, new diagnostic tools and new treatments, dedicated to personalized medicine in oncology. PRISM relies on cutting-edge molecular imaging and multi-omics technologies for clinical translational analysis, in vivo and real-time mass spectrometry coupled with robotics to guide the surgeon, 3D cell culture models and biopriting, and biotherapy developments via reprogramming (macrophages, astrocytes) and cell engineering (CAR-Macrophages). To develop its therapeutic approaches, PRISM is therefore interested in characterising the tumour microenvironment and the molecular mechanisms associated with the dialogue between tumour cells, immune cells, nerve cells and the microbiota (bacteria, viruses), focusing on breast cancer and glioblastoma.

PRISM is associated with the glycoproteomics laboratory of the Department of Chemistry at Yale University through an International Associated Laboratory, and with the private company OCR via a joint laboratory labelled by the Hauts de France region. PRISM also integrates the Organomics service platform, which enables the know-how and skills resulting from the laboratory’s research to be exploited. Organomics offers services in proteomics, lipidomics, mass spectrometry imaging, mixed 3D cell culture models with immune cells (organoids, explants and bioprinting) and extra-cellular vesicles. Finally, PRISM’s developments have led to the creation of the company IMABIOTECH and more recently to the emergence of the start-up CELEOS, which is bringing the SpiderMass

PRISM is an interdisciplinary laboratory integrating i.e. Biologists, molecular biologists, Biochemists, Chemists, and Physicians issued from University of Lille, Cancer Center Oscar Lambret (COL) and the University Hospital Center (CHU Lille).

The Technological Innovation axis arose from the MALDI Imaging Team (MIT) created in 2002 by Prof. I. Fournier devoted to MALDI MS Imaging (MALDI MSI). MIT was one of pioneer in Worldwide of MALDI MSI and is now one of the world leaders in spatially resolved tissue micro-proteomic guide by High Resolution MALDI MSI for clinical applications targeting precision medicine.

Since 2004, MIT researches were focused on i) technological developments and ii) clinical applications transversally to the second axis of theunit. MIT targets since its beginnings on the development of MALDI MSI first with improvements in i) tissue preparation for both Fresh frozen and Formalin–Fixed Paraffin-Embedded (FFPE) samples and ii) biomolecules identification with preserved spatial localization. This was pursed through the development of novel MALDI matrices (ionic matrices), of matrix deposition methods (spraying devices, automatic spotting with piezoelectric head), on-tissue micro-digestion and on-tissue tryptic peptide derivatization, unlocking FFPE tissue, bioinformatics (novel imaging software, MITICS, Principal-Component Analysis-Symbolic Discriminant Analysis method (PCA-SDA)), novel pre-spotted MALDI plates with ionic matrices, as well as targeted MALDI-MSI based on Tag-Mass.

The innovation axis is now focused is separated in two work packages so-called INTIMITY (For biomarkers Hunting) including Spatial XL-MS, IMHOTEP, BAT-MASS and GHOST and REALITY’MS (For personalized Diagnosis and prognosis) including SPIDERMASS and SNOOP-I. Clinical applications of INTIMITY was performed on Ovarian cancer (FIMBRIA, SENTIRAD).

The Therapeutic Innovation axis is organized in 2 integrated work packages which are translational from basic science to clinics. WP1 (ORPHEE) is focused on immune cells reprogramming for cancer therapy through macrophages reactivation (MACBETH, MAC-CAR, ESCULAPE) and WP2 (Caron: Caron on Oncology) is devoted to clinical application of in clinic (GLIOMIC, OMERIC) and more recently (MONET (MSCA), NANOTUMORS (AVIESAN PFA)).

Share this: